SCHEMBL4591920

SCHEMBL4591920

NCCCc1ccc(C(N)Cc2ccccc2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
MAOA P21397 2/20 0.40
EPHX1 P07099 1/20 0.38
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
GLS O94925 1/20 0.36
TAAR1 Q96RJ0 3/20 0.36
CYP2A6 P11509 3/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4591873 0.77 MAOA (0.55) CYP1A2MAOASMN1; SMN2CYP2D6CYP2C19
SCHEMBL4591816 0.76 ALDH1A1 (0.55) MAOAALDH1A1SMN1; SMN2GLSTAAR1
SCHEMBL3008598 0.73 CYP1A2 (0.45) CYP1A2MAOAEPHX1ALDH1A1SMN1; SMN2
SCHEMBL4592109 0.69 MCHR1 (0.47) MAOAALDH1A1SMN1; SMN2GAAL3MBTL1
SCHEMBL5421880 0.69 GLS (0.49) MAOAALDH1A1SMN1; SMN2HPGDMEN1
SCHEMBL3712032 0.68 CYP1A2 (0.46) CYP1A2MAOAEPHX1ALDH1A1SMN1; SMN2
SCHEMBL4591922 0.67 GBA1 (0.42) MAOAALDH1A1SMN1; SMN2GAAKMT2A
Amphetamine SCHEMBL28993698 0.66 SLC6A4 (0.70) MAOATAAR1CYP2A6SLC6A2SLC6A4
SCHEMBL4591085 0.65 BCAT2 (0.53) MEN1KMT2AHTR2ALOXL2
SCHEMBL52482 0.65 MAOA (0.85) CYP1A2MAOASMN1; SMN2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943231-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-16 EP disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
WO-2007048802-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 CYP1A2 667/4885MAOA 159/4885EPHX1 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.